34th International Symposium on ALS/MND

From 6 to 8 December 2023, more than 1300 people from all…

Av Floor Ooms.Publicerad December 22, 2023
34th International Symposium on ALS/MND

From 6 to 8 December 2023, more than 1300 people from all over the world gathered in Basel, Switserland for the 34th edition of the International Symposium on ALS/MND. After three online editions, this year the MND community could come together again in person.  

MND Association’s International Symposium on ALS/MND is the largest medical and scientific conference dedicated to ALS and MND research. Clinicians, researchers, health and social care professionals and even patient fellows came together to discuss the newest understanding of ALS and MND, make new connections and form new partnerships.

The three days were filled with keynote lectures, sessions on various topics from clinical trials to biomarkers and almost 400 poster presentations. One of the highlights of the Symposium was the closing session, which brought a patient with FUS-ALS trialing the drug Jacifusen onto the stage. The patient has the rare FUS mutation, which leads to an aggressive form of the disease: she wasn’t able to walk anymore and ended up in a coma. After taking the drug, she was now able to stand on the stage herself.  

Read more about the Symposium here.

 


Dela

Relaterade nyheter

Amylyx withdraws RELYVRIO/AMX0035 from U.S. and Canadian markets
Amylyx withdraws RELYVRIO/AMX0035 from U.S. and Canadian markets
Yesterday, the pharmaceutical company Amylyx announced that they are withdrawing the drug […]
Results of TUDCA-study: No effect of investigated compound
Results of TUDCA-study: No effect of investigated compound
The TUDCA-ALS consortium has announced the first findings of the TUDCA study, […]
Amylyx: no effect after analyzing phase 3 study
Amylyx: no effect after analyzing phase 3 study
The pharmaceutical company Amylyx announced the first results of the PHOENIX study. […]
Tofersen receives positive opinion from CHMP (EMA)
Tofersen receives positive opinion from CHMP (EMA)
The Committe of Medicinal Products for Human Use (CHMP) of the European […]